FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
Español 药物安全通讯 Drug Safety Communication (PDF - 62 KB) 2-3-2022 FDA Drug Safety Communication The U.S. Food and Drug Administration (FDA) is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) approved to treat two …